Archives: Search / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014
Jul 2, 2020 Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis
|
May 26, 2020 - Event scheduled for June 2, 2020 at 8am ET; featuring leading KOL Matthew Matasar, M.D. -
|
May 13, 2020 - Data to be Featured in the American Society of Clinical Oncology Annual 2020 Virtual Scientific Program on May 29, 2020 at 8:00 a.m. EDT -
|
- 83% overall response rate in patients with relapsed or refractory follicular lymphoma -
|
May 7, 2020 -- ME-401 global alliance with Kyowa Kirin executed, $100M in upfront payment and MEI eligible to receive up to an additional $582.5M in milestones --
|
-- MEI Pharma and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S.; MEI to book U.S. sales on 50-50 profit and cost sharing
|
Feb 6, 2020 -- MEI Starts Fiscal Third Quarter of 2020 with ~$104 Million in Cash --
|
